The FDA decision on the expanded use of Epcoritamab-bysp, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, is anticipated on June 28, 2024.Epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, is approved in the United States and Japan under the brand name EPKINLY, and in the European Union as TEPKINLY, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).Epcoritamab is being co-developed by Genmab (GMAB) and AbbVie (ABBV) as part of the companies' oncology collaboration.ABBV closed Wednesday’s trading at $154.79, down 0.35%.